Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra Birnkrant

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Hepatology (Baltimore, Md.)|April 11, 2012
Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjectsJiang Liu, Pravin R Jadhav, Shashi Amur, et al.
Antiviral Research|September 28, 2021
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's EvaluationKirk Chan-Tack, Patrick Harrington, Timothy Bensman, et al.
American Journal of Therapeutics|May 11, 2004
Regulatory toxicology perspectives on the development of botanical drug products in the United StatesKuei-Meng Wu, James Farrelly, Debra Birnkrant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2012
Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virusAlfred Sorbello, S Christopher Jones, Wendy Carter, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Hepatology (Baltimore, Md.)|April 11, 2012
Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjectsJiang Liu, Pravin R Jadhav, Shashi Amur, et al.
Antiviral Research|September 28, 2021
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's EvaluationKirk Chan-Tack, Patrick Harrington, Timothy Bensman, et al.
American Journal of Therapeutics|May 11, 2004
Regulatory toxicology perspectives on the development of botanical drug products in the United StatesKuei-Meng Wu, James Farrelly, Debra Birnkrant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2012
Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virusAlfred Sorbello, S Christopher Jones, Wendy Carter, et al.
Pageof 3